ライフサイエンスコーパス: alkylating agent

1 ore as well as on the aromatic moiety of the alkylating agent.

2 s as a topoisomerase inhibitor as well as an alkylating agent.

3 ng bromocrotonate as the activated methylene alkylating agent.

4 ine is a newly approved and better-tolerated alkylating agent.

5 N-ethylmaleimide (NEM), a cysteine-selective alkylating agent.

6 lex was more resistant to inactivation by an alkylating agent.

7 e in vitro and confers protection from a DNA-alkylating agent.

8 ivalent requiring metabolic breakdown to the alkylating agent.

9 , an imidazotetrazine-class chemotherapeutic alkylating agent.

10 ross a diverse cell line panel exposed to an alkylating agent.

11 ing regimen, with 73 also receiving a second alkylating agent.

12 yl trifluoromethanesulfonate as a reversible alkylating agent.

13 verse nucleophiles using methylarenes as the alkylating agent.

14 icrotubule toxin and a duocarmycin-class DNA-alkylating agent.

15 and can detect both gas- and solution-phase alkylating agents.

16 t severe, pulmonary vascular complication of alkylating agents.

17 s makes them significantly more sensitive to alkylating agents.

18 nd intrastrand cross-linking agents, but not alkylating agents.

19 h antimetabolites, T-cell inhibitors, and/or alkylating agents.

20 n spectra and signatures associated with DNA alkylating agents.

21 ylation strategy using simple olefins as the alkylating agents.

22 ersus-host disease regardless of exposure to alkylating agents.

23 poor growth in ARTEMIS deficiency and use of alkylating agents.

24 m to repair DNA adducts and are sensitive to alkylating agents.

25 e metabolism to form potent DNA minor groove-alkylating agents.

26 otizing scleritis may respond to IMT, mainly alkylating agents.

27 2-diketones using simple terminal olefins as alkylating agents.

28 ses, these compounds convert into active DNA-alkylating agents.

29 ge may protect the active site cysteine from alkylating agents.

30 es, which include ionizing radiation and DNA-alkylating agents.

31 unity and tumor clearance in response to DNA alkylating agents.

32 capacity to repair DNA damage induced by DNA alkylating agents.

33 tion with dexamethasone, anthracyclines, and alkylating agents.

34 s an important role by protecting cells from alkylating agents.

35 esistance to certain cancer chemotherapeutic alkylating agents.

36 phenylalanine) and involve Me2Zn or Et2Zn as alkylating agents.

37 arian damage include ovarian irradiation and alkylating agents.

38 was strongly correlated with sensitivity to alkylating agents.

39 f resistance to some cancer chemotherapeutic alkylating agents.

40 sions created by endogenous or environmental alkylating agents.

41 y in clinical trials to enhance therapy with alkylating agents.

42 Mitomycins are bioreductively activated DNA-alkylating agents.

43 primary aliphatic alcohols to be employed as alkylating agents.

44 adaptive response to exogenous nucleic acid-alkylating agents.

45 aggregates in the presence of oxidizing and alkylating agents.

46 reactive methyl donor, and by reaction with alkylating agents.

47 SCC foci formation and are hypersensitive to alkylating agents.

48 ed upon exposure to endogenous and exogenous alkylating agents.

49 ation of ketones using simple alkenes as the alkylating agents.

50 foci specifically upon exposure of cells to alkylating agents.

51 nse of malignant melanoma cells treated with alkylating agents.

52 ator compound for many types of carcinogenic alkylating agents.

53 %) or in association with rituximab (21.1%), alkylating agents (36.8%) or a combination of cyclophosp

54 patients), purine analogs (26 patients), or alkylating agents (39 patients).

55 ies), including proteasome inhibitors (91%), alkylating agents (91%), autologous stem cell transplant

56 ere treated with RT, and almost 40% received alkylating agent (AA) -containing chemotherapy (predomin

57 Cumulative exposure to alkylating agent (AA) was notably lower in the G studies

58 , we quantified cumulative doses of specific alkylating agents (AAs) and reconstructed radiation dose

59 Exposure of Escherichia coli to alkylating agents activates expression of AidB in additi

60 Compared with temozolomide, a clinical DNA-alkylating agent against glioma, 6OTD required lower con

61 Treatment with alkylating agents also was not significantly associated

62 at G4 targeting of this clinically important alkylating agent alters the overall mechanism of action.

63 Conditioning regimens consisted of an alkylating agent and fludarabine, and GVHD prophylaxis i

64 alidomide, pomalidomide, daratumumab, and an alkylating agent and had disease refractory to at least

65 rate that ALX, through its dual action as an alkylating agent and topoisomerase inhibitor, represents

66 hat the clinical efficacy of combinations of alkylating agents and anthracyclines are due to the abil

67 adiation and treatment with a combination of alkylating agents and anthracyclines.

68 otoxic agent with structural similarities to alkylating agents and antimetabolites, but which is non-

69 onse resulting from DNA crosslinking agents, alkylating agents and camptothecin.

70 s been increasingly used in combination with alkylating agents and dexamethasone.

71 esponse to replicative stress induced by DNA alkylating agents and greatly influences drug response i

72 duced by lysosomal injury resulting from DNA alkylating agents and hypotonic shock, whereas it promot

73 ive SCID suggest that minimizing exposure to alkylating agents and ionizing radiation is important fo

74 ne (1-MeA) is formed in DNA by reaction with alkylating agents and naturally occurring methyl halides

75 lites, but which is non-cross-resistant with alkylating agents and other drugs in vitro and in the cl

76 high-dose radiation (especially over 10 Gy), alkylating agents and procarbazine, at older ages, were

77 survival following first-line treatment with alkylating agents and purine analogs.

78 ated with defective apoptosis in response to alkylating agents and purine analogues.

79 articularly those who have been treated with alkylating agents and purine nucleoside analogs and woul

80 plausible cause-effect relationship between alkylating agents and PVOD.

81 ne questionnaire, and quantified exposure to alkylating agents and radiation therapy.

82 We quantified chemotherapy with alkylating agents and radiotherapy doses to the testes a

83 ses and related quaternary ammonium salts as alkylating agents and singlet oxygen sensitizers.

84 5), and a dose response was observed between alkylating agents and SMN rate (RR, 1.2/5,000 mg/m(2); 9

85 Linear dose responses were seen between alkylating agents and SMN rates and between anthracyclin

86 specifically increases in response to S(N)2 alkylating agents and to a lower extent to S(N)1 alkylat

87 compromise fertility, especially exposure to alkylating agents and whole body irradiation, which caus

88 ng adult (CAYA) cancer who were treated with alkylating agents and/or radiation, with potential expos

89 g with two alkylating agents (p=0.015 vs one alkylating agent) and last available pre-HSCT bilirubin

90 EN), to alkyl diazohydroxides (which are DNA-alkylating agents) and also aldehydes (HCHO from DMN and

91 tients, is associated with prior exposure to alkylating agents, and a high frequency of TP53 loss or

92 istant to conventional (e.g., dexamethasone, alkylating agents, and anthracyclines) or novel (e.g., t

93 nerated by chain-terminating nucleosides and alkylating agents, and base oxidation both in the nuclea

94 r-stable and inexpensive nitroalkanes as the alkylating agents, and delivers synthetically versatile

95 MGMT) in tumor correlates with resistance to alkylating agents, and depletion of MGMT activity can en

96 op1 inhibitors, but also to Top2 inhibitors, alkylating agents, and DNA synthesis inhibitors.

97 trobenzofurazan-based scaffolds, maleimides, alkylating agents, and electrophilic aldehydes, toward c

98 such as exposure to reactive oxygen species, alkylating agents, and many of the antibiotics targeting

99 intestinal cancer associated with exogenous alkylating agents, and that endogenous alkylation does n

100 health-related outcomes, such as exposure to alkylating agents, anthracyclines, radiotherapy, and sur

101 DNA-alkylating agents are commonly used to kill cancer cells

102 s in Diels-Alder reactions and electrophilic alkylating agents are described.

103 The mutagenic and cytotoxic effects of many alkylating agents are reduced by O(6)-alkylguanine-DNA a

104 uding antimetabolites, T-cell inhibitors and alkylating agents, are effective in many patients, allow

105 Dose escalation of alkylating agents as tested in this trial did not improv

106 s of mutations in yeast strains treated with alkylating agents, as well as in whole-exome and whole-g

107 The use of an alkene as the formal "alkylating" agent associated with the tolerance for nume

108 nt, testicular radiotherapy at any dose, and alkylating agents at cyclophosphamide equivalent doses o

109 Treatment of animals with the alkylating agent azoxymethane resulted in both liver tox

110 erapy with bortezomib, dexamethasone, and an alkylating agent (BDex+AA) is associated with improved b

111 disease can be cured with therapy without an alkylating agent, bleomycin, etoposide, or high-dose, ex

112 N) or CB-839, hypersensitize cancer cells to alkylating agents both in vitro and in vivo.

113 TH-302, a prodrug of the cytotoxic alkylating agent bromo-isophosphoramide mustard, is pref

114 repair kinetics and increases sensitivity to alkylating agents, but not other forms of DNA damage.

115 arious histologic subtypes more sensitive to alkylating agents, but they have no effect in wild-type

116 poxic microenvironment induces resistance to alkylating agents by activating targets in the mammalian

117 te here that halogenated benzothiazine-based alkylating agents can be utilized to rapidly measure the

118 Alkylating agents can induce sustained drug-free remissi

119 ored by depletion of Top1, illustrating that alkylating agents can trigger cytotoxic Top1-breaks.

120 Nitrosoureas, traditionally viewed as DNA alkylating agents, can also covalently modify proteins s

121 more than 50% decrease in the LD(50) for DNA-alkylating agent carmustine (BCNU), which is commonly us

122 10.5-41.6] since diagnosis) who had received alkylating agent chemotherapy but no radiation therapy.

123 Increasing doses of uterine radiation and alkylating agent chemotherapy were strongly associated w

124 ing immunologic alterations, treatments (eg, alkylating agent chemotherapy), genetic susceptibilities

125 al tumors who did (and did not) benefit from alkylating-agent chemotherapy with RT.

126 Given the activity of the lenalidomide-alkylating agent combination in myeloma, we designed thi

127 ients with prior exposure to fludarabine and alkylating agent combinations, and patients with prior e

128 eath induced by cyclophosphamide (CP), a DNA alkylating agent commonly used in chemotherapy.

129 increase in mutations and sensitivity to an alkylating agent compared with the WT hMPG.

130 rimary tumor, therapeutic radiation, but not alkylating agents, confer an increased risk of SNs.

131 one alone (control group) concomitantly with alkylating agents containing chemotherapy.

132 s-resistant drugs used for conditioning (eg, alkylating agents) could favor elimination of residual c

133 We report that the combined use of the alkylating agent cyclophosphamide (CTX) and an agonist a

134 -DNA-methyltransferase (MGMT), which repairs alkylating agent damage, is one such target.

135 rates for the activity of the major types of alkylating agents defined by their nucleophilic substitu

136 a and treatment with N-ethylmaleimide (thiol alkylating agent), dithiothreitol (disulfide reducing ag

137 Those with a summed alkylating agent dose (AAD) score of three or four or wh

138 2; 95% CI, -0.02 to 0.64), higher cumulative alkylating agent dose (AAD) score or treatment with cycl

139 subsequent sarcoma among those who received alkylating agent doses in the third tertile (RR, 14.9; 9

140 ed with pelvic irradiation and/or increasing alkylating agent doses were at risk for acute ovarian fa

141 ity ensuing from chemotherapy combining O(6)-alkylating agents (e.g., temozolomide) with pseudosubstr

142 tissue extracts, and the efficiencies of the alkylating agents enable completion of all three labelin

143 Direct normoxic PARP1 activation by a DNA alkylating agent enhanced Bnip3 expression, and caused B

144 ta define the dose-specific relation between alkylating agent exposure and semen variables in adult s

145 Alkylating agent exposure was associated with an 8.8-fol

146 Alkylating agent exposure was estimated using the cyclop

147 nt stem cell collection prior to significant alkylating agent exposure, given its potential deleterio

148 arly higher cumulative doses of platinum and alkylating agents, face increased SMN risk.

149 abine), 4-6 of 6 matched dUCB-other (n = 40; alkylating agent + fludarabine +/- TBI), and 8 of 8 (n =

150 Trichloroacetimidates are useful alkylating agents for aromatic amines, requiring only a

151 of maximizing the chemotherapeutic value of alkylating agents for cancer treatment.

152 nd their relationship to genotype and use of alkylating agents for conditioning.

153 thiol derivatives with Michael acceptors and alkylating agents furnished thioglycosides and (1,1)-thi

154 s underlying the sensitivity of IDE to thiol-alkylating agents has not been elucidated.

155 that might predict a better response to DNA alkylating agents have been identified in GBMs, except f

156 not significantly elevated after exposure to alkylating agents (hazard ratio, 1.27; 95% CI, 0.3 to 3.

157 protects cells from carcinogenic effects of alkylating agents; however, MGMT is silenced by promoter

158 anthracycline (HR, 2.6; 95% CI, 1.6-4.3) or alkylating agents (HR, 1.7; 95% CI, 1.2-2.5), non-breast

159 ed necrotic cell death, induced by cytotoxic alkylating agents, hyperactivation of poly-ADP-ribose po

160 pated and unknown DNA adducts induced by DNA alkylating agents in biological samples.

161 Crick faces of nucleobases are accessible to alkylating agents in canonical dsDNA and that Hoogsteen

162 icancer cotherapies, used as enhancements of alkylating agents in chemotherapy.

163 erase (MGMT), a key enzyme for resistance to alkylating agents in glioblastoma patients.

164 Due to the abundant presence of alkylating agents in living cells and the environment, D

165 ), radiation dose-volume, anthracyclines and alkylating agents in non-chest irradiated survivors, and

166 ht alcohols such as ethanol could be used as alkylating agents in this methodology.

167 was observed among survivors not exposed to alkylating agents included in the CED (P > 0.29).

168 ially increased sensitivity to commonly used alkylating agents, including cisplatin, indicating that

169 severe lesions that can be produced by many alkylating agents, including N-methyl-N'-nitro-N-nitroso

170 Alkylating agents induce cytotoxic DNA base adducts.

171 In wild-type animals DNA alkylating agents induce photoreceptor apoptosis and sev

172 reviously shown in tumor xenografts that DNA alkylating agents induce sporadic cell necrosis and regr

173 confirm the formation of PARP-1 DPCs during alkylating agent-induced base excision repair (BER) and

174 tidases and rapidly and selectively releases alkylating agents into tumor cells.

175 rolidinone (NMP) established that the active alkylating agent is the azetidinium ion, 4, 4-azoniaspir

176 oselectivity of ambident nucleophiles toward alkylating agents is a fundamental problem in heterocycl

177 However, use of preconditioning with alkylating agents is associated with a greater likelihoo

178 Exposure to high doses of alkylating agents is associated with increased risk of i

179 The benefit of cancer chemotherapy based on alkylating agents is limited because of the action of DN

180 terocycles using allyl or benzyl alcohols as alkylating agents is presented.

181 sm may not augment some regionally delivered alkylating agents, leading to a net increase in tumor si

182 under basic conditions in the presence of an alkylating agent leads to atropselective O-alkylation wi

183 Temozolomide (TMZ) is an alkylating agent licensed for treatment of high-grade gl

184 DNA alkylating agents like nitrogen mustard (NM) are easily

185 reatment following topoisomerase II poisons, alkylating agents, local radiation, hematopoietic stem c

186 Using thiol-alkylating agents, mass spectrometry, and an assay for a

187 cing viability in the face of treatment with alkylating agents (mechlorethamine), anthracylines (doxo

188 e, enhanced active JNK levels, and increased alkylating agent-mediated apoptosis.

189 replication slowing; upon treatment with the alkylating agent methyl methane sulfonate, cds1Delta mut

190 ar protein reorganization on exposure to the alkylating agent methyl methanesulfonate (MMS).

191 e products that modulate the toxicity of the alkylating agent methyl methanesulfonate (MMS).

192 leotide resolution in yeast treated with the alkylating agent methyl methanesulfonate (MMS).

193 ild-type and Aag(-/-) cells treated with the alkylating agent methyl methanesulfonate (MMS).

194 e was enhanced upon DNA damage caused by the alkylating agent methyl methanesulfonate and that the re

195 arly severe in mutant cells treated with the alkylating agent methyl methanesulfonate.

196 st Saccharomyces cerevisiae treated with the alkylating agent methyl methanesulfonate.

197 Cellular sensitivity to two monofunctional alkylating agents (methyl methane sulfonate and N-methyl

198 Administration of the DNA-alkylating agent methylazoxymethanol acetate (MAM) on em

199 ssays and potentiate the cytotoxicity of the alkylating agents methylmethane sulfonate and temozolomi

200 s-link in vitro and in HeLa cells exposed to alkylating agent methylmethanesulfonate (MMS).

201 to monensin but also to salinomycin and the alkylating agent, methylnitrosourea.

202 ystem, leads to increased sensitivity to the alkylating agent MMS and hyper-recombination in an oligo

203 312 helps to prevent tumour induction by the alkylating agent MNU, which predominantly caused T cell

204 t donor blood cells, modified in vitro by an alkylating agent (modified immune cells [MICs]), induced

205 The trichloroacetimidate alkylating agent must be a stable cation precursor for t

206 man lymphoblastoid cell lines exposed to the alkylating agent N-methyl-N'-nitro-N-nitrosoguanidine (M

207 h UV radiation and a minimal dose of the DNA-alkylating agent N-methyl-N'-nitro-N-nitrosoguanidine.

208 r rad50 after exposure to UV-C radiation, an alkylating agent (N-methyl-N'-nitro-N-nitrosoguanidine),

209 ly accelerated by treatment of mice with the alkylating agent, N-ethyl-N-nitrosourea (ENU), regardles

210 eficient mice were treated with a potent DNA alkylating agent, N-ethyl-nitrosourea (ENU), to induce s

211 Moreover, the current generated by the alkylating agent, N-ethylmaleimide, occluded the effect

212 The main therapeutic options include alkylating agents, nucleoside analogues, and rituximab.

213 F can be developed to enhance the effects of alkylating agents on cancer cells.

214 o had not had a response to rituximab and an alkylating agent or had had a relapse within 6 months af

215 cing intracellular NAD(+) depletion, such as alkylating agents or direct NAD(+) synthesis inhibitors,

216 phocytic leukemia (CLL) who are treated with alkylating agents or single-agent fludarabine, its signi

217 itivity was not observed upon treatment with alkylating agents or UV irradiation.

218 tive lesions, upon exposure to UV radiation, alkylating agents, or oxidative conditions.

219 multivariate analysis, conditioning with two alkylating agents (p=0.015 vs one alkylating agent) and

220 d after reduction of receptor reserve by the alkylating agent, phenoxybenzamine, as it reduced the ma

221 All patients received alkylating agent plus fludarabine; 792 received allograf

222 cacy compared with corticosteroids alone and alkylating agents plus corticosteroids to achieve comple

223 Although cytotoxic alkylating agents possessing two electrophilic reactive

224 a (WM) and closely related disorders include alkylating agents, purine analogs, and monoclonal antibo

225 agents in WM include monoclonal antibodies, alkylating agents, purine analogs, proteasome inhibitors

226 rgeting of KRAS mutant DNA using a synthetic alkylating agent (pyrrole-imidazole polyamide indole-sec

227 Treatment with alkylating agents resulted in a hypermutator phenotype a

228 with 100% sperm retrieval while exposure to alkylating agents resulted in a significantly lower sper

229 elative risk [RR], 2.9; 95% CI, 2.1 to 4.2), alkylating agents (RR, 2.2; 95% CI, 1.6 to 3.0), and epi

230 oses of radiation to the ovaries, increasing alkylating agent score, and a diagnosis of Hodgkin's lym

231 Treatment with alkylating agents, second-line therapy, and age older th

232 Monofunctional alkylating agents sensitize MGMT-deficient tumor cells t

233 a young age, as well as pre-BMT exposure to alkylating agents, should inform breast cancer screening

234 etic diseases, the use of MTX rather than an alkylating agent such as cyclophosphamide would be prefe

235 Other alkylating agents such as cyclic alkanes, ethers, and al

236 Alkylating agents such as temozolomide lose their effica

237 ssion confers significant sensitivity to DNA alkylating agents such as temozolomide, providing a natu

238 y especially benefit from treatment with DNA alkylating agents such as temozolomide.

239 Chemotherapeutic alkylating agents, such as bifunctional nitrogen mustard

240 Alkylating agents, such as cyclophosphamide, set up the

241 changes color upon the exposure to dangerous alkylating agents, such as iodomethane vapor, without th

242 of bases damaged by oxidative metabolism or alkylating agents, such as those commonly used in cancer

243 ER and enhancing the cytotoxic effect of DNA-alkylating agent Temozolomide (TMZ) in mismatch repair (

244 lowed by radiotherapy and treatment with the alkylating agent Temozolomide (TMZ), can extend patient

245 RvIII influences the sensitivity towards the alkylating agent temozolomide (TMZ).

246 tant radiation and chemotherapy with the DNA alkylating agent temozolomide (TMZ).

247 udes radiation and chemotherapy with the DNA alkylating agent temozolomide (TMZ).

248 tic response came from use of the S(N)1-type alkylating agent temozolomide in combination with ionizi

249 nergistic cytotoxicity of treatment with the alkylating agent temozolomide in combination with the PA

250 The alkylating agent temozolomide, commonly used in the trea

251 evealed that LCA exhibits synergism with the alkylating agent temozolomide, which engages BER through

252 increased invasiveness and resistance to the alkylating agent temozolomide.

253 s glioblastoma-resistant cancer cells to the alkylating agent temozolomide.

254 y radiotherapy and chemotherapy with the DNA alkylating agent temozolomide.

255 y the proteasome inhibitor bortezomib or the alkylating agent temozolomide.

256 platin, taxol and tamoxifen but not with the alkylating agents temozolomide (TMZ), carmustine and chl

257 ; tetrachlorobenzoquinone (TCBQ) is a potent alkylating agent that reacts with cellular thiols at a d

258 human lymphoblastoid cells were treated with alkylating agents that have different mechanisms of acti

259 tion damage by protecting DNA and destroying alkylating agents that have yet to reach their DNA targe

260 n the presence of sodium dodecyl sulfate and alkylating agents that irreversibly inhibit Ubl protease

261 Both classes of compound are potent alkylating agents that may need to be considered in futu

262 ic fibroblasts are specifically sensitive to alkylating agents that result in O6-methylguanine adduct

263 proaches with alkyl halides or sulfonates as alkylating agents, the use of unactivated olefins for al

264 es with increased therapeutic sensitivity to alkylating agent therapy.

265 of the cobalt complex with 0.75 mol % of the alkylating agent to afford the desired products in up to

266 red with different alcohols, and shown to be alkylating agents to a range of nucleophiles.

267 Here we show that the addition of common alkylating agents to growing cultures of Escherichia col

268 ent of polymers with methyl iodide (MeI), an alkylating agent, to convert polymer-bound tertiary amin

269 A and R69F mutants are more sensitive toward alkylating agent toxicity, revealing the key role of Arg

270 lthough the gene transcription is induced by alkylating agent treatment, the protein is degraded in v

271 Temozolomide (TMZ) is an oral alkylating agent used for the treatment of glioblastoma

272 Temozolomide (TMZ) is an oral alkylating agent used for the treatment of high-grade gl

273 od was applied to temozolomide, an important alkylating agent used in the treatment of brain tumors,

274 Temozolomide is a DNA-alkylating agent used to treat brain tumors, but resista

275 Oxazaphosphorines are alkylating agents used in routine clinical practices for

276 from the corresponding N-alkyl imidazole, an alkylating agent (usually MeI), and sodium borohydride (

277 n whose mothers were exposed to radiation or alkylating agents versus neither, the prevalence of anom

278 eloped a strategy to harness alkyl amines as alkylating agents via C-N bond activation.

279 on, corticosteroids, and chronic exposure to alkylating agents via distinct molecular routes involvin

280 A adducts based on the reactivity of the DNA alkylating agent was demonstrated by inclusion of an ion

281 An isoxazole-based alkylating agent was developed to selectively alkylate c

282 Pre-BMT exposure to alkylating agents was associated with an increased risk

283 Exposure to alkylating agents was observed in 83.8% of cases, mostly

284 laromustine (VNP40101M), a sulfonylhydrazine alkylating agent, was conducted in patients age 60 years

285 ch relies on the synthesis of (13)C-enriched alkylating agents, was applied to the production of 15-r

286 n histone deacetylase inhibitors (HDACi) and alkylating agents, we present the discovery of a series

287 ge, testicular radiotherapy, and exposure to alkylating agents were associated with LCF, which was as

288 TMZ is an alkylating agent which is water soluble.

289 oma cells to apoptosis following exposure to alkylating agents, while not affecting primary melanocyt

290 Cyclophosphamide (CPA) is a DNA alkylating agent widely used in cancer chemotherapy.

291 le mice with melphalan (MLP), a bifunctional alkylating agent widely used in chemotherapy, induces DN

292 Bendamustine hydrochloride is an alkylating agent with novel mechanisms of action.

293 4-(p-nitrobenzyl)pyridine (NBP), a trap for alkylating agents with nucleophilic characteristics simi

294 s to be employed as nonhazardous and greener alkylating agents with the formation of environmentally

295 re susceptible to bi- and tri-functional DNA alkylating agents with this phenotype readily complement

296 no optimal approach that uses standard dose-alkylating agents without significant late effects.

297 st the hypothesis that increased exposure to alkylating agents would be associated with decreased spe

298 s, a mild protocol using simple and abundant alkylating agents would have considerable use in the syn

299 an catalyze the hydrolysis of the potent DNA-alkylating agents yatakemycin (YTM) and CC-1065.

300 yes/no), radiation to the neck (yes/no), and alkylating agent (yes/no).